What is Toxys?
Toxys specializes in innovative in vitro toxicity screening solutions, designed to identify hazardous and potentially carcinogenic properties of novel compounds during the initial phases of product and drug development. The company offers a suite of proprietary assays, including ToxTracker and ReproTracker, which provide crucial mechanistic insights into genetic and developmental toxicology. By serving pharmaceutical, chemical, and consumer goods industries, Toxys facilitates both in-house screening and expert consultation, aiming to bolster safety evaluations while minimizing the need for animal testing.
How much funding has Toxys raised?
Toxys has raised a total of $1.6M across 1 funding round:
Other Financing Round
$1.6M
Other Financing Round (2020): $1.6M with participation from KIKK Capital
Key Investors in Toxys
KIKK Capital
KIKK Capital is an investor participating in the funding round. Their specific investment focus is not detailed, but their involvement suggests a strategic interest in the biotech and drug development sectors.
What's next for Toxys?
The recent major strategic investment signals a period of accelerated growth and market expansion for Toxys. This capital infusion is expected to fuel further development of its unique toxicity screening platforms and broaden its service offerings to a global clientele. With a focus on enhancing safety assessments and reducing reliance on traditional testing methods, Toxys is strategically positioned to capture a larger share of the burgeoning biotech safety market, potentially leading to further rounds of financing as it scales its operations and impact.
See full Toxys company page
